fox files

WHO Deploys National Pandemic Influenza Surveillance Grid in Egypt—270 Officers Trained for Real-Time Monitoring Across 30 Sentinel Sites

As countries engineer avian influenza bird flu pathogens without restraint.

The World Health Organization and Egypt’s Ministry of Health just completed a national-scale workshop training nearly 300 surveillance officers to expand real-time monitoring of influenza and other respiratory pathogens across the country.

The move comes as this website has been tracking multiple governments performing gain-of-function experiments on avian influenza “bird flu” pathogens (see below this article), raising worries of another orchestrated, man-made pandemic.

The WHO announcement frames the workshop as routine and annual, masking the scale of the expansion and the integration of surveillance functions under WHO guidance.

“The annual meeting and accompanying workshop on integrated surveillance of acute respiratory infections (ARIs), conducted by the Egyptian Ministry of Health and Population in collaboration with the World Health Organization (WHO) Country Office in Egypt, brought together around 270 public health professionals.”

More than a simple “meeting,” this represents a consolidation of a national respiratory surveillance grid.

Two hundred and seventy surveillance officers trained at once sounds more like a deployment than a workshop.

The framing as “annual” makes the expansion appear normal and non-threatening when, in reality, it marks a significant expansion of WHO’s operational footprint inside Egypt’s health system.

---

Thirty Sentinel Sites Feeding a Unified National Surveillance Grid

The announcement identifies the personnel being trained, revealing a full-spectrum surveillance workforce (epidemiology, clinical staff, data specialists) rather than a narrow set of influenza experts.

“The participants, all involved in surveillance, included epidemiologists, data officers, physicians, nurses and laboratory specialists drawn from 30 ARI sentinel sites across 15 governorates.”

This proves the surveillance integration is nationwide.

“Sentinel sites across 15 governorates” means Egypt’s surveillance network is now being unified under a single reporting system.

Bringing in data officers signals the transition to real-time digital surveillance and automated reporting pipelines that feed directly into WHO’s global systems.

A Surveillance Framework That Never Powers Down

The WHO announcement reveals the core mission: strengthen surveillance for influenza and all respiratory viruses—not limited to outbreaks or emergencies.

“The sessions aimed to strengthen national capacities in disease surveillance for influenza and other respiratory viruses and improve preparedness for respiratory disease threats, particularly those with pandemic potential.”

They want to treat all respiratory viruses—seasonal or otherwise—as potential triggers for global coordination.

The phrase “other respiratory viruses” quietly expands surveillance beyond influenza to include COVID, avian flu, MERS, and any future pathogen, making continuous monitoring the norm.

This is how perpetual surveillance infrastructures are justified.

The workshop covers multiple pathogen classes, including zoonotic viruses, merging animal-origin threats with routine respiratory surveillance.

“The discussions covered a wide range of topics, including updates on the global and national epidemiological situation of influenza, COVID-19, avian influenza, Middle East respiratory syndrome coronavirus (MERS-CoV) and zoonotic respiratory infections.”

So the system is designed to take in constant “signal noise” from zoonotic sources—livestock, poultry, wildlife.

Zoonotic data is always active, which means alert conditions can always be justified.

Folding zoonotic viruses into human surveillance pipelines is a central feature because it guarantees a steady stream of “pandemic potential” warnings.

WHO Uses ‘Performance Evaluations’ to Enforce Surveillance Compliance

The announcement describes the unification and standardization of national operating procedures, indicating that Egypt’s surveillance mechanics are being aligned directly with WHO standards.

“Participants reviewed standard operating procedures for ARI and influenza-like illness (ILI) sentinel surveillance and laboratory operations, alongside findings from performance evaluations.”

The mention of “performance evaluations” means WHO is grading Egypt’s compliance with global surveillance standards.

The evaluations will serve as a mechanism for harmonizing Egypt’s protocols with WHO’s prescribed methods.

This is an oversight structure.

Once surveillance is standardized, WHO essentially co-authors the national surveillance workflow.

Building the Digital Backbone of a Permanent Respiratory Surveillance State

The WHO press release goes on to introduce the digital component—data integration, dashboards, and real-time reporting—showing that Egypt’s network is being plugged into a centralized digital surveillance architecture.

“They explored how digital tools and platforms can enhance ARI data quality and timeliness and discussed data reporting through the National Electronic Disease Surveillance System (NEDSS) and the ARI/ILI Power BI dashboard which are used to collect, analyse and visualize respiratory surveillance disease data.”

The system they’re describing allows centralized ingestion of respiratory data across Egypt, instant analytics, automatic WHO reporting, and algorithmic signal detection.

The Power BI dashboard represents the command interface of a national respiratory surveillance grid.

This is the infrastructure required for automated “health security” triggers, border protocols, and potential digital health certifications.

PRET: WHO’s Framework for Perpetual Surveillance, Now Active in Egypt

The WHO directly names PRET, acknowledging that Egypt is now being operationally aligned with WHO’s new global framework that replaces traditional outbreak response with permanent readiness.

“The sessions also covered WHO’s Preparedness and Resilience for Emerging Threats (PRET) framework, an innovative approach designed to improve countries’ pandemic preparedness, emphasizing its alignment with Egypt’s national health security priorities.”

PRET is the system designed to bypass the need for treaty ratification by embedding WHO frameworks in national systems through “technical assistance.”

Once PRET is integrated, WHO gains operational influence during any declared emergency.

Naming PRET outright signals that Egypt’s infrastructure is now being shaped to meet PRET’s requirements for sustained respiratory surveillance and rapid WHO-driven response.

Bottom Line

Egypt’s new WHO-guided influenza and respiratory surveillance upgrade is a quiet rollout of PRET—a framework that centralizes global respiratory monitoring under WHO standards and feeds constant influenza, COVID, bird flu, MERS, and zoonotic signals into real-time digital dashboards.

This turns “preparedness” into a perpetual surveillance regime, where respiratory data becomes the trigger for future restrictions, emergency declarations, and global coordination.

What makes the timing more concerning is that these surveillance expansions are happening as multiple governments continue engineering avian influenza viruses with pandemic traits—yet none of these programs are being halted.

PRET ensures the monitoring grid is in place before the next laboratory-engineered pathogen emerges.

With 270 surveillance officials trained across 30 sentinel sites, Egypt’s national system is now synced to WHO’s operational architecture.

And this same PRET-aligned model is being replicated country by country, building a global respiratory surveillance system that never powers down.

UK Lab Engineers Chimeric H7N7 Bird Flu Hybrids From High-Path Genes, Allowing Asymptomatic Spread of Lethal Virus: Journal ‘Virology’

Two synthetic H7N7 hybrids demonstrated silent, high-risk shedding behavior in experimental chickens.

The United Kingdom’s top government virology lab engineered new avian influenza viruses using reverse genetics, according to an October paper in Virology documenting the deliberate construction and experimental infection of chickens with synthetic H7N7 avian influenza variants.

The study findings are revealed as the WHO builds a permanent international system for collecting, storing, and redistributing pathogens under its new Pandemic Agreement.

The work, performed at the Animal and Plant Health Agency (APHA-Weybridge), reconstructed the mutation pathway by which low-pathogenic bird flu transitions into a lethal high-path strain.

The study confirms that government researchers created two genetically engineered influenza viruses, altered at the exact molecular switch responsible for converting mild bird flu into its highly pathogenic form.

The paper—“Infection of point-of-lay hens to assess the sequential events during H7N7 high-pathogenicity avian influenza emergence at a layer premises”—states that APHA scientists generated two recombinant H7N7 viruses through reverse genetics (“RG”):

“Two viable RG rescued recombinant LPAIVs were genetically identical to the isolated H7N7-HPAIV except for the CS, with one containing a DBCS (H7N7-DBCS) and the other a SBCS (H7N7-SBCS).”

These engineered viruses were then used to infect groups of live hens under SAPO Level 4/ACDP Level 3 biocontainment—the UK’s highest animal-pathogen security facilities.

The bird flu experiment raises national security concerns, given that Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

Governments all over the world are performing the same experiments on bird flu pathogens.

---

Creating New Bird Flu Viruses With Engineered Cleavage Sites

The engineered viruses differed only at the hemagglutinin (HA) cleavage site, the key molecular feature that determines whether an avian influenza virus remains low-pathogenic or becomes systemically lethal.

• H7N7-SBCS: a synthetic virus with a single-basic cleavage site
• H7N7-DBCS: a synthetic virus with a di-basic cleavage site

Both constructs kept all internal genes identical to a known high-path H7N7 outbreak strain, meaning APHA researchers produced low-path versions of a high-path virus with engineered cleavage-site mutations.

The paper states:

“The SBCS, DBCS and MBCS (HPAIV) viruses were otherwise genetically identical (including the internal genes).”

In plain terms, they took the genome of a highly pathogenic bird flu virus, edited the cleavage site to make it “low-path,” and then infected chickens to observe how the high-path virus might emerge again.

This is the same cleavage-site mutation that historically turns H5 and H7 viruses into lethal strains.

The Engineered Viruses Showed New Functional Behavior

Although created as “low-path” models, the engineered viruses demonstrated new and concerning biological behavior:

• Infection rates differed sharply between the constructs.
• The DBCS-engineered virus behaved more like a high-path precursor.
• Birds exposed to engineered strains survived later high-path challenge—but 95% still shed high-path virus, creating silent spreaders.

The study reports:

“Prior H7N7-LPAIV exposure did not prevent H7N7-HPAIV replication… 20/21 (95%) shed H7N7-HP.”

That means infected birds carried and expelled high-path virus without dying, a dangerous epidemiological function not typical of standard high-path bird flu outbreaks.

This creates a superspreading scenario in which visibly healthy birds shed lethal virus into water, bedding, and surrounding environments.

The environmental sampling confirmed this:

“H7N7-HPAIV environmental contamination occurred… in drinking water and mixed straw/feces.”

A Step-by-Step Reconstruction of How High-Path Bird Flu Emerges

The study explicitly aimed to recreate the sequential mutation steps under which a low-path strain turns into a high-path one.

The authors describe the goal:

“Our current study aimed to model the sequential events… beginning with H7N7-LPAIV incursion, followed 2 weeks later by H7N7-HPAIV challenge.”

This experiment reproduces, in controlled conditions:

1. Introduction of engineered low-path virus
2. Mild, low-level infection
3. A second exposure to a high-path strain
4. Silent onward shedding of the high-path virus
5. Environmental contamination
6. Survival of spreading hosts

This combination of enhanced survival + sustained shedding is precisely the kind of phenotype that raises dual-use questions in influenza engineering.

Conducted in Government BSL-3/4 Facilities

All work occurred at APHA-Weybridge under strict containment:

“Experiments were carried out in UK approved SAPO level 4, ACDP level 3 biocontainment laboratories.”

SAPO Level 4 is one of the highest pathogen-containment designations in the UK, typically associated with agents capable of major agricultural or economic harm.

Bottom Line

A UK government virology lab:

• engineered two new influenza viruses,
• from a known high-pathogenic backbone,
• altered the cleavage site, the genetic switch controlling lethality,
• infected live hens with the engineered constructs,
• and documented how these modifications enabled silent high-path virus replication and shedding.

This work confirms the intentional creation of new influenza viruses and demonstrates functional behaviors—particularly prolonged shedding without mortality—that raise significant dual-use and biosecurity concerns.

The world may be one step closer to another lab-made pandemic.

Bird Flu Research Explodes 1,000% Worldwide—WHO, CDC, and EcoHealth Lead Rapid Expansion: ‘Journal of Infection and Public Health’. It’s Beyond Ridiculous and Has Been for A Long Time Now!

Bird flu publications skyrocket from fewer than 10 papers a year before 2010 to over 50 in 2025—with output expected to hit 111 by 2030, a tenfold surge.

A new Journal of Infection and Public Health paper published this month by Indian Council of Medical Research (ICMR) scientists reveals an unprecedented rise in bird flu–related research worldwide—and predicts that publications on avian influenza will nearly double by 2030, marking what the authors call “accelerating growth” in the field.

The data show that bird flu research output has exploded from fewer than 10 papers a year before 2010 to over 50 in 2025, with the authors projecting a jump to 111 by 2030—a tenfold surge in just two decades, signaling that bird flu has quietly become one of the fastest-expanding areas of global pathogen research.

The figures are based on data from Scopus, a global scientific database that includes most journals indexed in PubMed but extends far beyond biomedical research to cover environmental, veterinary, and policy studies.

This makes Scopus the broadest available measure of the worldwide surge in bird flu–related publications.

---

The revelation comes as this website has, for years, been raising alarms over the quiet expansion of international bird flu experiments and bird flu pandemic response infrastructure.

The new study, titled “Avian Influenza Research Through the Lens of One Health: A Bibliometric Study” (Elsevier, 2025), analyzed 315 publications on avian influenza between 2000 and 2025 and found that research has exploded since 2018.

The authors expect the trend to continue exponentially over the next five years.

Using a third-degree polynomial model, the team projected that the number of publications will grow from 62 in 2026 to 111 by 2030, with an R² of 0.93 indicating a strong upward trajectory.

“A marked increase occurred after 2018… Forecasts suggest continued growth, with the number of publications expected to rise from 62 in 2026 to 111 in 2030, reflecting increasing research interest and recognition” the paper reads.

The Post-2018 Acceleration

The new study identifies 2018 as the tipping point when H5N1 and One Health publications began to surge.

That timeline aligns with several key developments:

• The 2018–2019 launch of the WHO–FAO–OIE–UN pandemic coordination framework under “One Health.”
• The rollout of avian influenza vaccination programs in China, which reshaped global research priorities.
• The resurgence of EcoHealth Alliance’s field work and U.S. government contracts related to avian flu viruses.

By 2025, the publication rate had risen to 56 papers per year—the highest in two decades

WHO, CDC, and EcoHealth at the Center of the Growth

According to the paper’s institutional data, the U.S. Centers for Disease Control and Prevention (CDC) leads the world in bird flu and One Health research output, followed by the World Health Organization (WHO) and EcoHealth Alliance.

EcoHealth is the same organization whose NIH-funded work in Wuhan has been at the center of worldwide controversy over gain-of-function experiments.

Table 1 lists the CDC as having the highest number of publications (13) with 271 citations, followed by the World Health Organization (WHO) (11 publications) and EcoHealth Alliance (8 publications).

In other words, the primary institutions steering the One Health–avian influenza research ecosystem are the same ones historically involved in dual-use virology, pandemic simulation, and cross-species virus manipulation projects.

‘Enhanced Cross-Sectoral Collaboration’—A Code for Expansion

The authors conclude by urging the global scientific community to strengthen “cross-sectoral collaboration” and “sustained surveillance” in poultry and wild birds, warning against “undetected transmission chains in resource-limited settings.”

While framed as disease prevention, this language mirrors the same pandemic-preparedness justification that has fueled massive funding surges into high-containment labs (BSL-2 and BSL-3) and pathogen collection networks around the world.

The study’s repeated emphasis on “biosecurity,” “interdisciplinary cooperation,” and One Health “integration” signals that governments and international bodies are institutionalizing H5N1 work as a standing global priority, not a short-term emergency response.

Normalizing a Permanent Bird Flu Research Pipeline

The study’s authors celebrate this acceleration as a sign of “increasing research interest and recognition.”

But for many observers, it represents something far more concerning—the normalization of a permanent, internationally coordinated pandemic creation and response regime built around H5N1 bird flu.

The report openly ties its findings to global governance structures such as the WHO and the United Nations, stating that the One Health framework is essential for “multisectoral collaboration” and for guiding “policy and research agendas” on avian influenza.

In effect, the paper documents the institutionalization of bird flu research as a permanent fixture of global biosecurity policy—a shift that blurs the line between public health and biodefense, and raises serious questions about how far these programs will go.

Bottom Line

The new Journal of Infection and Public Health study confirms what many have suspected: since 2018, there has been a coordinated expansion of avian influenza research worldwide.

WHO, CDC, and EcoHealth Alliance are leading the charge, and the scientific community now projects that output to double by 2030.

Behind the rhetoric of “One Health” and “collaboration” lies a long-term global infrastructure for studying, modifying, and surveilling avian viruses — one that could easily serve both pandemic prevention and pandemic creation agendas.

The normalization of this permanent H5N1 research pipeline marks the next chapter in the international “pandemic preparedness” agenda — and the public deserves to understand what’s being built, and why.

HHS Builds $37.5M Bird Flu Pandemic Hospital Network—75 Facilities to Serve as Federal ‘Special Pathogen’ Centers

Internal NETEC document confirms H5N1 avian influenza preparedness at the core mission of new taxpayer funded hospital network.

The U.S. Department of Health and Human Services (HHS), through its Administration for Strategic Preparedness and Response (ASPR), is funding a $37.5 million national hospital expansion to prepare for H5N1 bird flu and other high-consequence pathogens, according to a newly released internal federal document issued by the National Emerging Special Pathogens Training and Education Center (NETEC).

NIH and NIAID—which are under HHS, led by Secretary Robert F. Kennedy Jr.—are funding experiments that create brand new bird flu pathogens, raising conflict of interest worries as well as questions about the government’s motives (see list of articles below this article detailing these many experiments).

NIAID chief Dr. Jeffery Taubenberger is directing U.S. tax dollars toward bird flu reverse genetics experiments while holding a patent for the carcinogenic BPL-based bird flu jab at the center of the Trump administration’s $500 million ‘Generation Gold Standard’ program—funding both the problem and the patented solution.

---

The new document—an internal Request for Proposal (RFP) dated October 15, 2025—details how HHS will use NETEC, a consortium of Emory University, the University of Nebraska Medical Center, and NYC Health + Hospitals/Bellevue, to distribute federal funds to 75 hospitals across the United States, converting them into federally designated “Level 2 Special Pathogen Treatment Centers” (SPTCs).

Each facility is eligible to receive $500,000 under the ASPR-funded NSPS Level 2 Special Pathogen Treatment and Network Development (STAND) Award.

The RFP’s stated purpose is to “accelerate the domestic health care system’s readiness for [high-consequence infectious diseases], such as H5N1, Ebola, and others.”

Per the document:

“Under the guidance of ASPR, NETEC is now awarding $37,500,000 in funding to 75 facilities ($500,000 per facility) as they work to meet the requirements of NSPS Level 2 facilities. The funding will support activities such as training health care personnel, upgrading infrastructure, and acquiring specialized equipment to ensure Level 2 facilities meet NSPS minimum capabilities. These efforts are expected to ultimately result in the verification of funded facilities as Level 2 SPTCs. This expansion significantly enhances the nation’s surge capacity and geographic reach for managing HCIDs.”

The move comes as governments all over the world say they are creating hybrid bird flu viruses in biolabs, raising national security fears of another pandemic, whether intentional or accidental.

Those same countries ramp up bird flu vaccine production and distribution.

Meaning, once again, governments are creating both the problem and “solution” to another pandemic, raising conflict-of-interest worries.

Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

H5N1 Avian Influenza Explicitly Listed as a Federal Priority

While the public press release announcing the grant avoided mentioning bird flu, the internal NETEC RFP directly names H5N1 avian influenza as a top threat driving the new hospital buildout.

“The emergence and sustained transmission of HCIDs, such as Ebola, mpox, and avian influenza (H5N1), have overwhelmed hospitals, exhausted critical resources, and underscored the necessity for coordinated efforts to protect health care workers while ensuring the delivery of safe and effective patient care.”

This wording makes clear that H5N1 preparedness—not just general infectious disease readiness—is a central justification for the $37.5 million initiative.

Federal Pandemic Infrastructure Expansion

Under ASPR’s direction, NETEC will administer the new program as part of the National Special Pathogen System (NSPS)—a tiered national network of pathogen treatment centers first created after the 2014–2016 Ebola outbreak.

The new Level 2 centers are described as “the backbone of a resilient, skilled response to special pathogen threats,” designed to serve as regional treatment hubs capable of handling clusters of patients during future high-consequence disease outbreaks.

The funding will support:

• Upgrading isolation infrastructure,
• Purchasing specialized containment equipment,
• Training staff in special pathogen protocols, and
• Coordinating with existing Level 1 Regional Emerging Special Pathogen Treatment Centers (RESPTCs).

Awardees must demonstrate “substantial progress towards meeting the minimum capabilities of a Level 2 NSPS facility” by the end of the funding period.

‘Level 2’ Centers Will Treat Patients for the Duration of Illness

Each Level 2 facility, the RFP explains, must have “the capacity to deliver specialized care to clusters of patients suspected of or infected by a special pathogen” and “serve as the primary patient care delivery center.”

Notably, funded hospitals must also agree to:

“Serve as regional and national assets and accept patients from outside of the United States or outside their respective state, county, or local jurisdiction if requested.”

That clause effectively integrates participating hospitals into the federal pandemic command structure under ASPR oversight, expanding the U.S. government’s ability to move special pathogen cases across state or national lines.

Institutionalization of Permanent Biosecurity Infrastructure

The NETEC RFP uses unmistakable national security language, describing high-consequence infectious diseases (HCIDs) as threats to “the nation’s health, economy, and national security.”

It emphasizes what it characterizes as the need for “enhanced biosecurity frameworks, robust clinical readiness, and surge capacity across hospitals,” positioning the Level 2 expansion as a cornerstone of HHS’s long-term pandemic preparedness architecture.

The RFP even notes that NETEC “has demonstrated its critical role in strengthening national health security by coordinating National Special Pathogen System responses to novel respiratory pathogens, mpox, and Lassa fever.”

In other words, the federal government is now formally embedding outbreak containment systems inside civilian hospitals, justified by avian influenza and other potential zoonotic spillover threats.

Timeline & Implementation

Applications for the NSPS Level 2 STAND Award opened October 15, 2025, and close December 2, 2025.

Final selections are expected by January 5, 2026, with the official “period of performance” scheduled from January 5 through June 29, 2026.

Eligible applicants must have:

• An onsite emergency department,
• Airborne infection isolation rooms,
• Critical care and inpatient capacity, and
• A sufficient baseline of resources to achieve Level 2 verification.

The RFP explicitly prohibits use of the funds for direct clinical care or research—focusing instead on infrastructure, staff training, and equipment acquisition.

From COVID Lessons to Bird Flu Systems

NETEC was originally established in 2015 after the U.S. treated imported Ebola cases.

During the COVID-19 pandemic, it served as a national training and coordination body for pathogen response across hospitals.

Now, under ASPR’s expanded authority, NETEC’s mission has evolved from temporary outbreak response to permanent pandemic infrastructure building, with H5N1 preparedness front and center.

The RFP states that the expansion “significantly enhances the nation’s surge capacity and geographic reach for managing HCIDs,” embedding what amounts to federally funded containment capacity across the entire U.S. hospital network.

Bottom Line

The internal NETEC document reveals that HHS’s Administration for Strategic Preparedness and Response (ASPR) is quietly constructing a nationwide bird flu hospital network under the banner of “special pathogen preparedness.”

The $37.5 million program explicitly cites H5N1 avian influenza as a primary threat and converts 75 hospitals into federally integrated treatment hubs for future high-risk pathogen outbreaks.

This marks yet another major escalation in the institutionalization of permanent pandemic infrastructure inside the United States, built through administrative expansion under the HHS biosecurity apparatus.

NIH-Funded Mount Sinai Scientists Engineer New Bird Flu Franken-Virus Chimera in New York: Journal ‘Vaccine’

Peer-reviewed study confirms reverse-genetics construction of a synthetic avian–human influenza hybrid in New York City through $150 million gov’t contract.

A new Vaccine journal study published earlier this month reveals that scientists at the Icahn School of Medicine at Mount Sinai in New York have engineered a synthetic chimeric bird flu virus by splicing genetic segments from multiple influenza strains—avian, human, and laboratory-adapted—into a single live construct grown in chicken eggs.

The risky work was done in the name of “vaccine development,” exposing how, time and again, vaccine production serves as a legal and moral shield for the same dual-use genetic manipulation routinely used to create potential bioweapons.

The project was funded by the U.S. National Institutes of Health (NIH), which is led by Dr. Jay Bhattacharya.

The bird flu experiment raises national security concerns, given that Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

Countries all over the world are quietly performing dangerous gain-of-function-like bioweapons experiments on bird flu pathogens while simultaneously developing bird flu countermeasures like vaccines and antivirals, raising conflict-of-interest worries.

The new lab-made bird flu virus, named cH15/3HK14N2HK14, was assembled through reverse genetics, a technique that builds a fully functional virus from cloned DNA.

The team was led by Dr. Florian Krammer and Dr. Eduard Puente-Massaguer, both of Mount Sinai’s Department of Microbiology, with collaborators from Duke University and the University of Vienna.

According to the paper:

“Viruses were generated by reverse genetics.”

The construct combines three separate viral lineages:

• H15 head: from A/shearwater/West Australia/2576/1979 (H15N9), an avian seabird flu.
• H3 stalk and N2 neuraminidase: from A/Hong Kong/4801/2014 (H3N2), a human seasonal flu strain.
• Internal genes: from A/Puerto Rico/8/1934 (H1N1), a long-used lab strain that serves as the genetic backbone for research.

Per the study:

“For the group 1 cH8/1Cal09N1Cal09 virus, the H8 head domain was derived from the HA of A/mallard/Sweden/24/2002 (H8N4) and the HA stalk domain and the NA from A/California/04/2009 (H1N1). For the group 2 cH15/3HK14N2HK14 virus, the H15 head domain was derived from the HA of A/shearwater/West Australia/2576/1979 (H15N9), while the HA stalk domain and NA belong to A/Hong Kong/4801/2014 (H3N2). The internal genes of both viruses were derived from A/Puerto Rico/8/1934 (H1N1).”

In plain terms, Mount Sinai scientists merged three different influenza viruses—bird, human, and laboratory—into a single hybrid.

---

Serial Passaging Caused Genetic Mutation

The researchers then passaged the chimeric virus nine times in embryonated chicken eggs, allowing it to adapt and mutate.

They report that:

“Two different mutations were detected in the HA coding sequence at moderate proportions (53–65 %) … variations in the frequency of different polymorphisms were also detected in the HA, NA, and PB2 coding sequences along with changes in the non-coding regions (NCR) of the PB1 and PB2 gene segments.”

In other words, the hybrid virus mutated across key genetic regions associated with host adaptation and replication efficiency—hallmarks of gain-of-function evolution.

Chemical Treatment & Residual Surfactant

To inactivate and split the virus, Mount Sinai’s team exposed it to beta-propiolactone (βPL or BPL)—a known carcinogenic and mutagenic agent—and Triton X-100, a detergent recognized for environmental toxicity and endocrine disruption.

Even after processing, researchers kept residual Triton X-100 between 0.02% and 0.08% to “improve stability,” meaning trace levels of the chemical remained in the finished vaccine material.

Animal Testing & Resistance to Inactivation

Mount Sinai’s team injected mice with 5 micrograms of hemagglutinin (HA) derived from the chimeric viruses, confirming a strong immune response—proof that the lab-created material remained biologically and antigenically active.

Even more concerning, the paper reveals that the cH15/3HK14N2HK14 virus required higher concentrations of BPL to fully neutralize than other influenza strains.

The authors note that 0.025% BPL failed to inactivate the virus within 24 hours, forcing them to double the concentration to 0.05% to achieve total inactivation.

Per the study:

“The demonstration of absence of virus replication after βPL inactivation is a requirement by regulatory agencies. To optimize this, a 24 h virus inactivation kinetics study was conducted for both cH8/ 1Cal09N1Cal09 and cH15/3HK14N2HK14 viruses at 4 ◦C. The absence of HA titer after two sequential rounds of egg injection with neat sample was considered as an indication of complete virus inactivation. For the cH8/ 1Cal09N1Cal09 virus, 0.025 % (v/v) βPL resulted in complete viral inactivation after 24 h incubation. Treatment with 0.025 % (v/v) βPL was not enough to inactivate the cH15/3HK14N2HK14 virus within 24 h, so the concentration of βPL was increased to 0.05 % (v/v). In these conditions, complete virus inactivation was demonstrated.”

This means the Mount Sinai chimera Franken-virus demonstrated greater resistance to chemical inactivation, a red flag in vaccine manufacturing and biosafety settings where even small lapses could lead to accidental exposure.

U.S. Taxpayer Funding & Big Pharma Conflicts of Interest

The project was funded through the NIH’s Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (here, here), totaling $151 million.

The CIVICs program, launched in September 2019, is involved in more than 125 preclinical, clinical, and manufacturing studies related to influenza vaccines as of 2025.

The National Institute of Allergy and Infectious Diseases (NIAID), led by Dr. Jeffery Taubenberger and part of NIH, provided $51 million in first-year funding for the program.

Mount Sinai disclosed that it has filed patents on these chimeric influenza viruses, listing Krammer and Puente-Massaguer as inventors, and that Krammer personally consults for Merck, Pfizer, GSK, Sanofi, CureVac, and Seqirus, among others.

In effect, the same laboratory designing and manipulating these synthetic viruses also profits from their commercial vaccine applications.

Context: Global Bird Flu Engineering Boom

The revelation comes amid a wave of government-funded bird flu research around the world.

The U.S. Department of Agriculture recently declared avian influenza a “permanent emergency,” ensuring uninterrupted funding even during government shutdowns.

At the same time, foreign institutions—from Kazakhstan and South Korea, to Switzerland, to the U.K. and China—have engaged in similarly risky gain-of-function avian flu experiments combining multiple virus lineages.

Mount Sinai’s work confirms that such chimeric bird flu construction is also happening in New York City, under NIH contract funding and academic oversight.

Bottom Line

The new Vaccine paper makes clear:

• A man-made bird flu chimera was constructed in New York City,
• Mutated through repeated egg passaging,
• Chemically treated with carcinogenic and toxic compounds,
• And patented for future commercialization.

While branded as vaccine research, these experiments demonstrate dual-use biotechnology—capable of both “protection” and potential catastrophic misuse—occurring inside U.S. borders.

Given the grave national security implications and the proven global track record of lab-origin pandemics, there must be an immediate, permanent moratorium on all pathogen-enhancement and chimeric virus experiments—no matter how they’re labeled, licensed, or justified.

USDA, Energy Department Engineer New Bird Flu Franken-Virus in Georgia Lab: Journal ‘Avian Diseases’

Birds injected with hybrid pathogen became contagious.

A new study published last month in Avian Diseases confirms that U.S. Department of Agriculture (USDA) researchers in Athens, Georgia, engineered a synthetic H5N9 avian influenza “bird flu” virus using reverse genetics—a gain-of-function method that assembles viruses from cloned DNA.

The U.S. Department of Energy, led by Secretary Chris Wright, helped fund the project.

Official Photo of Chris Wright, Secretary of the U.S. Department of Energy (Energy.gov)

The alarming experiment raises national security concerns.

The new paper explains that the vaccine virus was “generated by reverse genetics … using the HA gene of TK/IN/22 modified to be low pathogenic and N9 NA gene of A/blue winged teal/Wyoming/AH0099021/2016 with the remaining gene segments from the PR8 influenza strain.”

In plain terms, the USDA built a three-part bird flu chimera:

• The H5 gene came from a 2022 highly pathogenic bird flu outbreak in Indiana turkeys.
• The N9 gene came from a wild duck virus in Wyoming.
• The backbone genes came from PR8, a decades-old laboratory strain optimized for high viral replication.

The resulting hybrid—an H5N9-PR8 chimera—does not exist in nature.

The risky work was done in the name of “vaccine development,” revealing how regularly potential bioweapons are created under the guise of claimed public health research.

It is not widely understood that vaccine production often serves as a legal and moral shield for the same dual-use genetic manipulation techniques utilized to build offensive biological agents.

Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

The USDA’s new virus creation comes as the agency recently elevated bird flu to a permanent national emergency, guaranteeing uninterrupted funding for its manipulation and vaccine programs even during a government shutdown—cementing bird flu as a standing, institutional priority within America’s biosecurity and biodefense apparatus.

USDA is led by Secretary Brooke Rollins, who in February rolled out a $1 billion plan for fighting bird flu, confirming the agency is orchestrating both the problem and solution to a future avian influenza pandemic.

Secretary of Agriculture Brooke L. Rollins (USDA.gov)

---

Lab-Enhanced Replication Ability

The USDA researchers admit that the lab-adapted PR8 strain was selected because it “replicates to high titers in eggs,” granting the chimera the ability to multiply rapidly—a function the wild H5N1 and N9 donor viruses lacked.

That change means the USDA-created virus can reach massive viral loads under laboratory or vaccine-manufacturing conditions—a textbook gain of function.

Synthetic Alteration of Pathogenicity

The hemagglutinin (HA) gene from the deadly turkey virus was manually modified to make it appear “low pathogenic”:

“…using the HA gene of TK/IN/22 modified to be low pathogenic…”

This involved editing the HA cleavage site, the molecular switch that determines whether a virus causes mild or fatal disease.

That modification created an artificial genetic variant—a version of H5 that has never existed in wild populations.

Vaccinated Birds Still Shed Virus

Once constructed, the chimera was injected into live turkeys to test “vaccine efficacy.”

Despite being described as “inactivated,” all vaccinated turkeys still shed live virus:

“All turkeys shed detectable levels of virus at one or more time points.”

Even with 100% survival, up to 100% of vaccinated birds in certain groups excreted viral particles from their throats or cloacae—meaning that vaccinated flocks could continue spreading the virus silently.

According to the data, all vaccinated groups shed virus, and some even developed mild symptoms:

“Two vaccinated turkeys in the 9 wk vaccination group exhibited clinical signs … mild unilateral periorbital swelling … mild lethargy from 6 to 7 DPC.”

The USDA’s own summary acknowledges that reducing virus shedding is “a critical aspect of HPAI vaccine efficacy,” but their inactivated vaccine did not eliminate it—meaning even “protected” birds could become long-term reservoirs.

Reverse-Genetics = Dual-Use Research

The USDA team produced the hybrid using a “reverse-genetics system,” the same technology used in dual-use gain-of-function research.

The system reconstructs viruses gene by gene, allowing scientists to mix and match segments from different species.

The resulting construct—combining avian and laboratory lineages—represents a clear functional enhancement over its wild counterparts, achieving:

• Higher replication capacity (PR8 internal genes),
• New antigenic profile (H5N9 combination), and
• Synthetic attenuation (edited cleavage site).

USDA & Energy Department Funding

All authors—Jiho Lee, Chang-Won Lee, Sherif Ibrahim, David Suarez, and Erica Spackman—are government scientists employed by the U.S. National Poultry Research Center, part of the USDA’s Agricultural Research Service.

That means the same federal agency responsible for regulating poultry biosecurity is now engineering and testing new bird flu viruses in its own facilities—a conflict of interest for biosafety oversight.

The research was conducted under federal funding agreement “6040-32000-081-00D,” and the authors acknowledged additional support through a U.S. Department of Energy–USDA interagency agreement—confirming dual-agency collaboration in the creation of engineered pathogens.

Creating the Problem to Sell the Solution

While marketed as “vaccine research,” the study’s implications go far beyond poultry health.

The paper explicitly explores DIVA (Differentiating Infected from Vaccinated Animals) systems—tools designed to track infections in vaccinated flocks rather than prevent them.

“The NI-ELLA assay successfully detected antibodies to the challenge virus in vaccinated chickens and showed its potential application for DIVA-VI of vaccinated turkeys.”

In short: instead of eradicating H5N1, the USDA is normalizing its coexistence—vaccinating birds that continue to carry and shed lab-derived influenza strains.

Bottom Line

Under the label of “vaccine development,” the U.S. Department of Agriculture has quietly engineered a novel bird flu chimera that combines genetic material from a lethal turkey virus, a wild duck strain, and a lab-optimized replication platform.

The resulting H5N9 hybrid:

• Does not exist in nature,
• Acquired new laboratory functions, and
• Was tested in live turkeys that continued shedding virus.

What this means is that U.S. government scientists are performing gain-of-function work inside USDA labs — creating, modifying, and testing synthetic avian influenza viruses that have the very properties of concern in dual-use bioweapons research.

In the absence of clear congressional oversight or international accountability, this kind of federally funded pathogen engineering inside domestic labs doesn’t just blur the line between defense and offense—it invites catastrophic biosecurity failure on U.S. soil.

Given that the COVID pandemic killed millions of Americans, there should be a permanent moratorium on all pathogen creation and manipulation—even when it’s done in the name of drug development.

It’s time for a permanent moratorium on all pathogen creation and manipulation—no matter how it’s justified—because Americans should never again be forced to bankroll both the killer cause of a crisis and the government’s profitable “solution” to it.

Kazakhstan, South Korea Engineer Live Bird Flu–Tuberculosis Franken-Virus: Journal ‘Veterinary World’

The discovery coincides with a U.S. policy move placing bird flu and bovine tuberculosis under indefinite emergency status—raising urgent questions of intent and global coordination.

A new study published last month in Veterinary World confirms that scientists from Kazakhstan and South Korea have engineered a live hybrid virus that combines genetic material from avian influenza “bird flu” and Mycobacterium bovis, the bacterium that causes bovine tuberculosis.

Governments all over the world are quietly generating an army of new bird flu pathogens, without a peep from the mainstream media or popular influencers.

The new chimeric influenza–tuberculosis pathogen was created inside Kazakhstan’s government-run Research Institute for Biological Safety Problems, with technical collaboration from Seoul National University in South Korea, and funding provided by Kazakhstan’s Ministry of Education and Science.

According to the authors, they “generated recombinant influenza viruses expressing M. bovis antigens ESAT-6 and TB10.4 using a standard reverse genetic system.”

In plain terms, the team used reverse-genetics, a lab method that assembles new viruses from cloned DNA, to insert tuberculosis genes into the flu genome—creating a synthetic viral-bacterial hybrid.

They further explain: “We produced a vaccine strain expressing the M. bovis mycobacterial proteins ESAT-6 and TB10.4 from the NS1 open reading frame of the avian influenza virus through reverse genetics with virus replication in embryonated chicken eggs.”

In other words, the tuberculosis genes were physically embedded inside the influenza virus’s NS1 gene, then amplified inside live bird embryos to generate infectious viral particles.

The NS1 gene in bird flu controls the virus’s ability to evade the host immune system and replicate efficiently inside infected cells.

The generation of a bird flu-tuberculosis Franken-virus comes as the U.S. Department of Agriculture’s FY2026 emergency funding plan quietly placed both highly pathogenic avian influenza and bovine tuberculosis under the same permanent “no-year” emergency funding status—elevating bird flu and tuberculosis research, including gain-of-function and vaccine development, to federally protected, continuous-operation programs even during a full government shutdown.

Taken together, the creation of a live bird flu-tuberculosis chimera overseas and the U.S. government’s decision to grant both pathogens permanent emergency status raise serious national security concerns.

The timing and alignment of these actions suggest more than coincidence—raising pressing questions about whether global agencies and their partners are merely preparing for future outbreaks, or deliberately coordinating the groundwork for one.

Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

---

Insertion of ‘Alien Sequences’

The scientists note that the NS1 gene “was modified to include the antigen sequences.”

That means the flu virus’s genetic code was deliberately edited to carry foreign bacterial fragments.

They add: “The virus was attenuated by modifying the NS1 protein by inserting alien sequences derived from the target protein amino acid region 124.”

Translated, the researchers confirm they altered the flu virus by altering a key protein and inserting “alien” genetic material—a literal cross-species fusion between virus and bacterium.

Microscopic Confirmation of the Hybrid Virus

Under an electron microscope, “the virion morphology of the recombinant viruses corresponded to that of the avian influenza viruses. The virions were spherical and enclosed in a bilayer supercapsid with ~10 nm glycoprotein spikes, which determine the hemagglutinative or neuraminidase activity.”

Simply put, even after being spliced with tuberculosis genes, the new organism was said to still look and behave like an influenza virus—complete with its purported spike-covered shell used for cell infection.

Verified ‘Genetic Chimeric Structure’

Molecular testing showed the genetic combination held together across generations:
“The first cloning stage showed a preserved genetic chimeric structure in the NS1 genome segment, as confirmed by RT-PCR.*”

Meaning: laboratory sequencing confirmed the hybrid DNA remained intact, proving the chimeric virus was genetically stable and self-replicating.

The study’s schematic further details the exact makeup:

“The recombinant segment of the non-structural protein 1 (NS1) gene express[es] the ESAT-6 and TB10.4 antigens of the virulent 0078-Mycobacterium bovis-8/RIBSP strain. The yellow rectangle represents the NS1 regions, while the green rectangles represent the mycobacterial genes.”

In plain language, the figure shows flu genes (yellow) fused with tuberculosis genes (green)—a clear depiction of genetic grafting across species.

Replication & Stability

The team reported the new virus replicated efficiently:

“The recombinant vector expressing the mycobacterial antigens showed a high hemagglutination activity of 1:128 at an infectious activity level of lg 6.75 ± 0.07 EID50/0.2 mL.”

In other words, each dose contained roughly five million infectious particles, confirming robust viral growth.

They also verified the genetic insert stayed stable:

“To evaluate the stability of the inserted gene, five serial passages of the virus were carried out in embryonated chicken eggs at 34 °C.”

This means the hybrid virus could be re-grown repeatedly without losing its tuberculosis genes—evidence of lasting biological stability.

Bottom Line

The Veterinary World study confirms that scientists from Kazakhstan’s Research Institute for Biological Safety Problems and Seoul National University created a genetically engineered, self-replicating organism that merges the genetic material of tuberculosis bacteria with avian influenza virus.

Their own words describe a “recombinant influenza virus” with a “preserved genetic chimeric structure” and “alien sequences” inserted into the NS1 gene—a live, replicating influenza–tuberculosis chimera manufactured inside bird embryos.

The timing of this creation—coinciding with the U.S. government’s decision to grant both bird flu and bovine tuberculosis permanent emergency funding—raises profound national security questions.

It suggests a coordinated international framework in which the same pathogens now being engineered in foreign labs are simultaneously being prioritized and federally protected under U.S. biosecurity policy.

Whether framed as “vaccine research” or “preparedness,” these programs collectively point to a globally synchronized architecture of high-risk pathogen development and continuity planning—one that operates beyond public consent, outside normal oversight, and increasingly blurs the line between defense and deliberate design.

USDA Declares Bird Flu a Permanent Emergency, Ensures Funding Continuity Even During Government Shutdown

Avian influenza officially elevated above nearly every other disease in the country’s federal continuity plan—after USDA rolled out $1 billion bird flu plan earlier this year.

Secretary of Agriculture Brooke Rollins remarks announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)

The U.S. Department of Agriculture (USDA) has quietly confirmed that highly pathogenic avian influenza (H5N1)—the same “bird flu” virus currently at the center of international gain-of-function experiments and vaccine production—will continue to receive emergency funding even during a full government shutdown.

According to the USDA’s FY2026 Lapse of Funding Plan, issued last month, the agency’s Animal and Plant Health Inspection Service (APHIS) will keep drawing from so-called “no-year emergency funding balances” to sustain select animal and plant disease programs indefinitely.

Out of all diseases, bird flu made the list.

And unlike normal appropriations, no-year funds never expire.

“No-year emergency funding balances will support continuation of animal and plant health emergency programs including new world screwworm, highly pathogenic avian influenza, exotic fruit flies, African swine fever, bovine tuberculosis, and rabies,” the plan states on page 23.

The move comes after USDA Secretary Brooke Rollins in February rolled out a $1 billion plan for fighting bird flu.

While governments are creating both the problem and the solution for a future bird flu pandemic (as they did for COVID-19), the USDA is now ensuring that the funding pipeline for those very operations—viral manipulation, surveillance, and pharmaceutical development—remains permanently open, immune to congressional oversight, public objection, or even the collapse of the federal government itself.

USDA’s recent actions confirm that bird flu has been formally elevated to a standing national emergency—an institutionalized, self-perpetuating priority that guarantees the continuation of biosecurity and vaccine programs regardless of political process, fiscal restraint, or the existence of an actual outbreak.

The United Nations and the World Health Organization are also mobilizing their own pandemic command structure around bird flu—with the WHO reactivating its global influenza emergency framework and the U.N. convening 500 international “experts and decision-makers” for the world’s first-ever “Global Dialogue” on bird flu coordination—a synchronized effort that mirrors the pre-COVID buildup of global pandemic infrastructure.

---

A Stunning Admission: Bird Flu Funding Can’t Be Stopped

In plain terms, this funding admission means that even if Congress collapses, the White House freezes, and all other federal operations are shuttered—the U.S. government will still keep funding bird flu programs.

Not monkeypox, Ebola, Marburg, or Chikungunya—but bird flu.

That level of protection is extraordinary.

Bird flu has been singled out for continuous, uninterruptible funding, on par with national defense and nuclear security operations.

No other infectious disease—human or animal—is afforded this kind of permanent continuity status in the USDA’s emergency budget architecture.

This isn’t normal policy language.

It’s an institutional declaration that bird flu is being treated as a standing national emergency, whether or not an actual outbreak exists.

What does the government know that we don’t?

And why does the United States continue to perform dangerous gain-of-function experiments on bird flu viruses when Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation?

Why does NIAID Director Dr. Jeffery Taubenberger hold a patent on the carcinogenic BPL technology at the center of the Trump administration’s $500 million bird flu vaccine program if he’s simultaneously funding experiments that generate never-before-seen, hybrid “Frankenstein” bird flu pathogens?

Just before the COVID pandemic, former NIAID Director Anthony Fauci was funding similar dangerous coronavirus experiments while the government was simultaneously developing a COVID vaccine.

Taken together, these problem-solution orchestration patterns raise national security, conflict of interest, and informed consent concerns.

A Signal of Pre-Planned Pandemic Operations

This USDA no-year emergency bird flu funding revelation comes as federal and international partners are already pouring billions into bird flu vaccine stockpiling, cancer-linked bird flu jabs, and bird flu gain-of-function lab experiments.

The USDA’s emergency funding clause guarantees that none of these operations—research, surveillance, vaccine testing, or field trials—will ever be interrupted, even if the rest of the government runs out of money.

This continuity effectively locks in a permanent and unprecedented bird flu response infrastructure, insulating bird flu activities from public debate, budget oversight, or congressional defunding efforts.

In other words, the government has pre-authorized bird flu as the one disease that can bypass the normal political process.

Prioritizing Bird Flu Over All Else

The USDA’s plan lists only six diseases eligible for automatic emergency funding: H5N1 bird flu, African swine fever, rabies, bovine tuberculosis, exotic fruit flies, and New World screwworm.

Yet only one of these—H5N1—is currently the focus of global vaccine production, laboratory gain-of-function work, and pandemic-level preparedness programs.

This choice is not accidental.

It shows that H5N1 has been politically and financially elevated above all other animal diseases as the presumed next pandemic threat.

It also means federal agencies are ensuring that avian flu vaccine and biosecurity operations will proceed uninterrupted, regardless of whether Congress approves a budget or the public objects.

Implications: A Built-In Bird Flu Apparatus

The USDA’s FY2026 Lapse of Funding Plan document proves that the U.S. government has already built the infrastructure to respond to an H5N1 “emergency” long before any such emergency exists.

It guarantees:

• Constant funding for H5N1 surveillance, lab work, and vaccine production.
• Operational continuity across USDA, BARDA, and CEPI-linked vaccine programs.
• No congressional check or pause on H5N1-related activities—even under government collapse.

When paired with the ongoing gain-of-function experiments enhancing H5N1’s ability to infect mammals, this shows the federal government isn’t merely preparing for a bird flu outbreak—it’s institutionalizing it as a permanent national focus.

Bottom Line

The USDA’s FY2026 emergency funding plan quietly exposes how H5N1 bird flu has been hardwired into the U.S. government’s permanent emergency infrastructure.

While nearly every other program would go dark in a shutdown, bird flu remains protected—its funding guaranteed, its operations untouchable, its continuity automatic.

This is not routine budgeting.

It’s a declaration of institutional permanence for a virus that has not yet caused a human pandemic—an extraordinary move that places bird flu response programs on the same level as national defense and nuclear security.

By pre-authorizing H5N1 funding to flow indefinitely, the federal government has created a self-sustaining pandemic apparatus—one that cannot be defunded, debated, or democratically constrained.

Taken together, the USDA’s emergency funding clause, NIAID’s gain-of-function work, and the global vaccine push reveal a chilling reality: H5N1 isn’t just being prepared for—it’s being positioned.

The government has pre-selected bird flu as the next pandemic—and built a financial machine to keep that plan running forever.

Is the next bird flu pandemic no longer a question of if, but when?